Navigation Links
MannKind to Present at the Piper Jaffray Healthcare Conference
Date:11/20/2007

VALENCIA, Calif., Nov. 20 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Piper Jaffray Healthcare Conference on November 27, 2007 at 10:30 AM ET at the Pierre Hotel in New York, NY.

Interested parties can access a link to the live web cast of the presentation in the Investor Relations section of the Company's website at http://www.mannkindcorp.com. A replay of the presentation will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.


'/>"/>
SOURCE MannKind Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
5. Avicena Group to Present at Noble Financial Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. CEL-SCI to Present at the Noble Financial Conference
10. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
11. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader in ... new Director of Product Strategy. In this role, Michelle will ... sub-teams to guide in the development of iLab products. Her ... maximum possible benefit to the scientific community by offering the ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... lend materials new characteristics are generally complicated and therefore ... to astonishment when scientists report on new methods which ... they use economically priced starting materials but also do ... framework made of polystyrene This is exactly ...
... BioSpace added Kansas to its annual promotional campaign of biotechnological, ... , , ... , , (Logo:   ... The leading employment Web site for the ...
... , July 29 Omeros Corporation (Nasdaq: ... equity financing facility under which it may sell up to ... to Azimuth Opportunity, Ltd. (the "investor") over a 24-month period. ... free to enter into and consummate other equity, debt and ...
Cached Biology Technology:Empa grows 'sea urchin'-shaped structures 2BioSpace Showcases the Midwest's Growing Life Science Region 2BioSpace Showcases the Midwest's Growing Life Science Region 3Omeros Secures $40 Million Committed Equity Financing Facility 2Omeros Secures $40 Million Committed Equity Financing Facility 3Omeros Secures $40 Million Committed Equity Financing Facility 4
(Date:7/10/2014)... the Straits of Mackinac reverse direction every few days, ... would quickly contaminate shorelines miles away in both lakes ... Michigan study commissioned by the National Wildlife Federation. , ... animations, oil from a hypothetical pipeline break reached Mackinac ... Blanc Island after two days. All three islands are ...
(Date:7/10/2014)... The yellow crazy ant Anoplolepis gracilipes is ranked ... responsible for catastrophic ecological impacts on islands. A new study ... examines and assesses the effects and dangers of the ... of the mature palm forest of the Valle de Mai, ... palm forest of Valle de Mai is a unique ecosystem ...
(Date:7/10/2014)... Columbia University Medical Center (CUMC) researchers have created a ... retinitis pigmentosa (RP), a leading cause of vision loss. ... of induced pluripotent stem (iPS) cell technology to transform ... as a patient-specific model for disease study and preclinical ... H. Tsang, MD, PhD, showed that a form of ...
Breaking Biology News(10 mins):Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 2Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 3Invasion of yellow crazy ant in a Seychelles UNESCO palm forest: Threats and solutions 2Patient-specific stem cells and personalized gene therapy 2Patient-specific stem cells and personalized gene therapy 3
... the National Center for Supercomputing Applications was barely ... Connection Machines, CM-2, was just being installed, and ... University of Illinois, launched the Theoretical Biophysics Group ... analytical tools of physics and chemistry, coupled with ...
... Heidelberg, Germany, September 17th, 2009 / b3c newswire ... station PROcellcare based on a 96 well plate. ... licensing partner EMBL (European Molecular Biology Laboratory). ... live cells (in vitro) under the microscope with ...
... Researchers at the Department of Biochemistry and Molecular ... revealed the process by which proteins with a ... lateral sclerosis, familial amyloidotic polyneuropathy, familial amyloidotic cardiomyopathy, ... carried out an analysis of their 3D structure ...
Cached Biology News:Symposium marks 20th anniversary of Theoretical and Computational Biophysics Group 2Symposium marks 20th anniversary of Theoretical and Computational Biophysics Group 3Symposium marks 20th anniversary of Theoretical and Computational Biophysics Group 4New Automatic cell feeding station PROcellcare for life cell imaging 2Mechanism related to the onset of various genetic diseases revealed 2Mechanism related to the onset of various genetic diseases revealed 3
... 26] to Presenilin 2 Alzheimer's disease ... the disease carry mutations in the presenilin ... protein (APP). These disease-linked mutations result in ... amyloid-beta (main component of amyloid deposits found ...
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
Biology Products: